Renata PLC (DSE:RENATA)

Market Cap	45.35B
Revenue (ttm)	44.03B
Net Income (ttm)	2.37B
Shares Out	114.70M
EPS (ttm)	20.64
PE Ratio	19.15
Forward PE	12.73
Dividend	5.50 (1.39%)
Ex-Dividend Date	Nov 18, 2025

Volume	11,928
Average Volume	26,323
Open	402.00
Previous Close	398.40
Day's Range	394.00 - 402.00
52-Week Range	372.00 - 668.00
Beta	-0.09
RSI	38.15
Earnings Date	Jan 25, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia...

• Industry: Pharmaceutical Preparations
• Founded: 1972
• Employees: 8,366
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: RENATA

Financial Performance

In 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.